Sep 2026· Expert Opinion on Pharmacotherapy· Vol 27, pp. 1565 - 1580· 0 citations· 101 references
Medicine
TL;DR
Developments support the emerging role of JAK-directed therapy as a significant advancement in the management of vitiligo by enabling targeted modulation of specific inflammatory pathways central to vitiligo pathophysiology.
Abstract
ABSTRACT Introduction Vitiligo is a chronic autoimmune condition characterized by progressive loss of melanocytes and the development of depigmented skin lesions. Increasing evidence highlights the pivotal role of dysregulated JAK–STAT signaling in disease pathogenesis. Areas covered A literature search was performed using PubMed/MEDLINE, to identify relevant studies published up to January 2026, about the contribution of JAK–STAT–dependent pathways to vitiligo progression, IFN-γ–induced chemokine production (CXCL9 and CXCL10), recruitment of cytotoxic CD8+ T lymphocytes, and the involvement of tissue-resident memory (T < sub > RM) T cells in maintaining localized immune responses. The effects of JAK inhibition across multiple cell populations, including melanocytes, keratinocytes, and immune cells were examined. Current clinical data regarding both topical and systemic JAK inhibitors in the context of targeted repigmentation strategies. Expert opinion Unlike conventional systemic immunosuppressive therapies, JAK inhibitors enable targeted modulation of specific inflammatory pathways central to vitiligo pathophysiology. Future therapeutic success will likely depend on appropriate patient selection, optimal timing of intervention, and rational combination approaches aimed at sustaining repigmentation and reducing relapse risk. Collectively, these developments support the emerging role of JAK-directed therapy as a significant advancement in the management of vitiligo.
Introduction Vitiligo is a chronic autoimmune depigmentation skin disorder characterized by the acquired loss of melanocytes, with a complex multifactorial pathophysiology. Among the potential predisposing factors, some drugs, including monoclonal antibodies, have been associated to disease onset. Methods The aim of th...
M. Romagnuolo, C. Moltrasio, L. Rossi et al.· Frontiers in Immunology· 0 citations
Vitiligo is one of the most common and clinically challenging chronic depigmentary disorders. Current treatments, including corticosteroids, phototherapy, and JAK inhibitors, remain limited by incomplete or non-durable repigmentation, necessitating novel mechanism-based therapeutic strategies. Autophagy, classically d...
Shuai-Shuai Hu, Lei Yong, Jia-Hui Wang et al.· Frontiers in Cell and Develo...· 0 citations
Janus kinase (JAK) inhibitors have revolutionized the management of inflammatory dermatoses over recent decades; however, discontinuation is frequently associated with rapid disease recurrence, known as the “relapse” phenomenon, which complicates long-term disease control. Current evidence on the molecular pathophysiol...
S. Moradi, A. Rostami, Vesal Hasani et al.· Discover Immunity· 0 citations
The expanding therapeutic pipeline in HS reflects a shift towards precision medicine and pathway-specific interventions, and novel biologics, dual cytokine-inhibition strategies and bispecific agents represent an emerging therapeutic paradigm.
T. Tzellos, A. Liakou, P. Garbayo-Salmons et al.· Journal of the European Acad...· 0 citations
This paper advocates for a multi-target therapeutic approach in SS, aiming to mitigate the intricate cytokine network and restore glandular function, ultimately improving patient outcomes.
A. V. Poznyak, A. Vatlin, D. Borodko et al.· International Journal of Dru...· 0 citations
Abstract Background and objectives Lichen planus (LP) is a chronic, lymphocytic, inflammatory skin disorder that can affect the skin, hair follicles, nails, and mucous membranes. It has limited treatment options. The pathogenesis of LP includes inflammation driven by interferons and the Janus kinase–signal transducer a...
Atheer G. Almutairi, Leena Aloraini, Abeer G. Almutairi et al.· Annals medicus· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.